Jacques Colinge

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8361915/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The CRAPome: a contaminant repository for affinity purification–mass spectrometry data. Nature Methods, 2013, 10, 730-736.	9.0	1,353
2	An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nature Immunology, 2009, 10, 266-272.	7.0	935
3	Gene essentiality and synthetic lethality in haploid human cells. Science, 2015, 350, 1092-1096.	6.0	773
4	Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 2007, 110, 4055-4063.	0.6	600
5	IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nature Immunology, 2011, 12, 624-630.	7.0	422
6	Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature, 2014, 508, 222-227.	13.7	336
7	Artemisinins Target GABAA Receptor Signaling and Impair α Cell Identity. Cell, 2017, 168, 86-100.e15.	13.5	330
8	OLAV: Towards high-throughput tandem mass spectrometry data identification. Proteomics, 2003, 3, 1454-1463.	1.3	291
9	The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13283-13288.	3.3	274
10	Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. Cancer Research, 2017, 77, 2722-2734.	0.4	263
11	SingleCellSignalR: inference of intercellular networks from single-cell transcriptomics. Nucleic Acids Research, 2020, 48, e55-e55.	6.5	257
12	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia, 2009, 23, 477-485.	3.3	254
13	A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nature Chemical Biology, 2010, 6, 291-299.	3.9	254
14	Viral immune modulators perturb the human molecular network by common and unique strategies. Nature, 2012, 487, 486-490.	13.7	249
15	Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nature Methods, 2013, 10, 307-314.	9.0	192
16	Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling. Nature Methods, 2015, 12, 1055-1057.	9.0	183
17	CD14 is a coreceptor of Toll-like receptors 7 and 9. Journal of Experimental Medicine, 2010, 207, 2689-2701.	4.2	181
18	A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death and Disease. 2015. 6. e1767-e1767.	2.7	157

#	Article	IF	CITATIONS
19	A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nature Chemical Biology, 2011, 7, 787-793.	3.9	156
20	Charting the molecular network of the drug target Bcr-Abl. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7414-7419.	3.3	146
21	Interactome of Two Diverse RNA Granules Links mRNA Localization to Translational Repression in Neurons. Cell Reports, 2013, 5, 1749-1762.	2.9	130
22	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. Chemical Science, 2015, 6, 2449-2456.	3.7	127
23	Early-onset inflammatory bowel disease and common variable immunodeficiency–like disease caused by IL-21 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1651-1659.e12.	1.5	124
24	General Statistical Modeling of Data from Protein Relative Expression Isobaric Tags. Journal of Proteome Research, 2011, 10, 2758-2766.	1.8	120
25	Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nature Communications, 2014, 5, 5360.	5.8	116
26	Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nature Immunology, 2016, 17, 1361-1372.	7.0	114
27	Functional Dissection of the TBK1 Molecular Network. PLoS ONE, 2011, 6, e23971.	1.1	110
28	Industrial-scale proteomics: From liters of plasma to chemically synthesized proteins. Proteomics, 2004, 4, 2125-2150.	1.3	103
29	Differential Proteomics via Probabilistic Peptide Identification Scores. Analytical Chemistry, 2005, 77, 596-606.	3.2	102
30	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nature Chemical Biology, 2012, 8, 905-912.	3.9	96
31	A reversible gene trap collection empowers haploid genetics in human cells. Nature Methods, 2013, 10, 965-971.	9.0	90
32	Proteomic analysis of human cataract aqueous humour: Comparison of one-dimensional gel LCMS with two-dimensional LCMS of unlabelled and iTRAQ®-labelled specimens. Journal of Proteomics, 2011, 74, 151-166.	1.2	79
33	High-performance peptide identification by tandem mass spectrometry allows reliable automatic data processing in proteomics. Proteomics, 2004, 4, 1977-1984.	1.3	74
34	The Lipid-Modifying Enzyme SMPDL3B Negatively Regulates Innate Immunity. Cell Reports, 2015, 11, 1919-1928.	2.9	74
35	Genome-wide diversity and gene expression profiling of Babesia microti isolates identify polymorphic genes that mediate host-pathogen interactions. Scientific Reports, 2016, 6, 35284.	1.6	74
36	CD4+ T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2. Nature Immunology, 2014, 15, 439-448.	7.0	70

#	Article	IF	CITATIONS
37	TLR 2 and CD14 Mediate Innate Immunity and Lung Inflammation to Staphylococcal Panton–Valentine Leukocidin In Vivo. Journal of Immunology, 2011, 186, 1608-1617.	0.4	68
38	A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia, 2010, 24, 44-50.	3.3	67
39	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. American Journal of Hematology, 2012, 87, 1010-1016.	2.0	67
40	Initial characterization of the human central proteome. BMC Systems Biology, 2011, 5, 17.	3.0	66
41	Virulence Factor NSs of Rift Valley Fever Virus Recruits the F-Box Protein FBXO3 To Degrade Subunit p62 of General Transcription Factor TFIIH. Journal of Virology, 2014, 88, 3464-3473.	1.5	65
42	In vitro andin silico processes to identify differentially expressed proteins. Proteomics, 2004, 4, 2333-2351.	1.3	63
43	A Comparative Proteomic Study of Human Skin Suction Blister Fluid from Healthy Individuals Using Immunodepletion and iTRAQ Labeling. Journal of Proteome Research, 2012, 11, 3715-3727.	1.8	62
44	Quantitative proteomics of aqueous and vitreous fluid from patients with idiopathic epiretinal membranes. Experimental Eye Research, 2013, 108, 48-58.	1.2	58
45	Introduction to Computational Proteomics. PLoS Computational Biology, 2007, 3, e114.	1.5	56
46	Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. Immunity, 2015, 43, 974-986.	6.6	50
47	The RNAâ€binding protein HuR/ELAVL1 regulates IFNâ€Î²ÂmRNA abundance and the type I IFN response. Europea Journal of Immunology, 2015, 45, 1500-1511.	n 1.6	49
48	Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 2016, 127, 362-365.	0.6	49
49	The Triggering Receptor Expressed on Myeloid Cells 2 Inhibits Complement Component 1q Effector Mechanisms and Exerts Detrimental Effects during Pneumococcal Pneumonia. PLoS Pathogens, 2014, 10, e1004167.	2.1	46
50	Assessing peptide <i>de novo</i> sequencing algorithms performance on large and diverse data sets. Proteomics, 2007, 7, 3051-3054.	1.3	42
51	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Molecular Systems Biology, 2013, 9, 705.	3.2	42
52	A time-resolved molecular map of the macrophage response to VSV infection. Npj Systems Biology and Applications, 2016, 2, 16027.	1.4	42
53	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene, 2015, 34, 3780-3790.	2.6	40
54	A strongly nonlinear problem arising in glaciology. ESAIM: Mathematical Modelling and Numerical Analysis, 1999, 33, 395-406.	0.8	39

#	Article	IF	CITATIONS
55	A Surface Biotinylation Strategy for Reproducible Plasma Membrane Protein Purification and Tracking of Genetic and Drug-Induced Alterations. Journal of Proteome Research, 2016, 15, 647-658.	1.8	39
56	A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nature Chemical Biology, 2017, 13, 771-778.	3.9	39
57	An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B. Molecular Cancer Therapeutics, 2011, 10, 1846-1856.	1.9	37
58	Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era. Frontiers in Oncology, 2017, 7, 83.	1.3	36
59	Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. Blood Advances, 2021, 5, 1540-1551.	2.5	35
60	OLAV-PMF:  A Novel Scoring Scheme for High-Throughput Peptide Mass Fingerprinting. Journal of Proteome Research, 2004, 3, 55-60.	1.8	34
61	Detecting the impact of sequencing errors on SAGE data. Bioinformatics, 2001, 17, 840-842.	1.8	29
62	Using iTRAQ Combined with Tandem Affinity Purification to Enhance Low-Abundance Proteins Associated with Somatically Mutated EGFR Core Complexes in Lung Cancer. Journal of Proteome Research, 2011, 10, 182-190.	1.8	29
63	A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. Oncogene, 2014, 33, 2531-2539.	2.6	29
64	A Comprehensive Analysis of the Dynamic Response to Aphidicolin-Mediated Replication Stress Uncovers Targets for ATM and ATMIN. Cell Reports, 2016, 15, 893-908.	2.9	29
65	The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics, 2020, 10, 4383-4394.	4.6	29
66	The chemokine interleukinâ€8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia. Molecular Oncology, 2008, 2, 272-281.	2.1	27
67	Acid Elution and One-Dimensional Shotgun Analysis on an Orbitrap Mass Spectrometer: An Application to Drug Affinity Chromatography. Journal of Proteome Research, 2009, 8, 4753-4765.	1.8	27
68	Systems biology analysis of proteinâ€drug interactions. Proteomics - Clinical Applications, 2012, 6, 102-116.	0.8	27
69	Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Journal of Clinical Investigation, 2019, 130, 612-624.	3.9	27
70	MIG–differential gene expression in mouse brain endothelial cells. NeuroReport, 2002, 13, 9-14.	0.6	26
71	InSilicoSpectro:Â An Open-Source Proteomics Library. Journal of Proteome Research, 2006, 5, 619-624.	1.8	24
72	The Prognostic Impact of the Aryl Hydrocarbon Receptor (AhR) in Primary Breast Cancer Depends on the Lymph Node Status, International Journal of Molecular Sciences, 2019, 20, 1016	1.8	24

#	Article	IF	CITATIONS
73	MetaBlasts: tracing protein tyrosine phosphatase gene family roots from Man to Drosophila melanogaster and Caenorhabditis elegans genomes. Gene, 2000, 253, 137-143.	1.0	23
74	Improved peptide charge state assignment. Proteomics, 2003, 3, 1434-1440.	1.3	23
75	A Computational Approach to Analyze the Mechanism of Action of the Kinase Inhibitor Bafetinib. PLoS Computational Biology, 2010, 6, e1001001.	1.5	23
76	Affinity Purification Strategies for Proteomic Analysis of Transcription Factor Complexes. Journal of Proteome Research, 2013, 12, 4018-4027.	1.8	21
77	Identification of Kinase Inhibitor Targets in the Lung Cancer Microenvironment by Chemical and Phosphoproteomics. Molecular Cancer Therapeutics, 2014, 13, 2751-2762.	1.9	21
78	Targeting a cell state common to tripleâ€negative breast cancers. Molecular Systems Biology, 2015, 11, 789.	3.2	21
79	MASPECTRAS 2: An integration and analysis platform for proteomic data. Proteomics, 2010, 10, 2719-2722.	1.3	20
80	The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling. Theranostics, 2021, 11, 3565-3579.	4.6	20
81	IsobarPTM: A software tool for the quantitative analysis of post-translationally modified proteins. Journal of Proteomics, 2013, 90, 77-84.	1.2	19
82	Machine Learningâ€Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening. Advanced Science, 2020, 7, 2000486.	5.6	19
83	Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia. Malaria Journal, 2017, 16, 493.	0.8	17
84	Building and exploring an integrated human kinase network: Global organization and medical entry points. Journal of Proteomics, 2014, 107, 113-127.	1.2	16
85	Experiments in Searching Small Proteins in Unannotated Large Eukaryotic Genomes. Journal of Proteome Research, 2005, 4, 167-174.	1.8	15
86	A Miniaturized Chemical Proteomic Approach for Target Profiling of Clinical Kinase Inhibitors in Tumor Biopsies. Journal of Proteome Research, 2013, 12, 4005-4017.	1.8	15
87	A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL. PLoS ONE, 2013, 8, e77155.	1.1	15
88	Comprehensive Comparative and Semiquantitative Proteome of a Very Low Number of Native and Matched Epstein–Barr-Virus-Transformed B Lymphocytes Infiltrating Human Melanoma. Journal of Proteome Research, 2014, 13, 2830-2845.	1.8	15
89	A Systematic Statistical Analysis of Ion Trap Tandem Mass Spectra in View of Peptide Scoring. Lecture Notes in Computer Science, 2003, , 25-38.	1.0	9
90	Peptide Fragment Intensity Statistical Modeling. Analytical Chemistry, 2007, 79, 7286-7290.	3.2	8

#	Article	IF	CITATIONS
91	Deconvolution of Targeted Protein–Protein Interaction Maps. Journal of Proteome Research, 2012, 11, 4102-4109.	1.8	8
92	Experimental characterization of the human non-sequence-specific nucleic acid interactome. Genome Biology, 2013, 14, R81.	13.9	7
93	Stress and velocity fields in glaciers: Part I. Finite-difference schemes for higher-order glacier models. Journal of Glaciology, 1998, 44, 448-456.	1.1	7
94	TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens. BMC Bioinformatics, 2014, 15, 98.	1.2	6
95	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. Analytical Chemistry, 2019, 91, 15500-15508.	3.2	6
96	Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. International Journal of Cancer, 2019, 145, 1299-1311.	2.3	6
97	MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis. Scientific Reports, 2021, 11, 5752.	1.6	6
98	Mechanisms underlying the cooperation between loss of epithelial polarity and Notch signaling during neoplastic growth in <i>Drosophila</i> . Development (Cambridge), 2022, 149, .	1.2	6
99	An R package for generic modular response analysis and its application to estrogen and retinoic acid receptor crosstalk. Scientific Reports, 2021, 11, 7272.	1.6	5
100	Stress and velocity fields in glaciers: Part II. Sliding and basal stress distribution. Journal of Glaciology, 1998, 44, 457-466.	1.1	4
101	Multiple and Sequential Data Acquisition Method: An Improved Method for Fragmentation and Detection of Cross-Linked Peptides on a Hybrid Linear Trap Quadrupole Orbitrap Velos Mass Spectrometer. Analytical Chemistry, 2013, 85, 1454-1461.	3.2	2
102	Enhancing cognate target elution efficiency in gel-free chemical proteomics. EuPA Open Proteomics, 2015, 9, 43-53.	2.5	2
103	Towards a screening test for cancer by circulating DNA analysis Journal of Clinical Oncology, 2019, 37, e13146-e13146.	0.8	2
104	Mass spectrometry has married statistics: uncle is functionality, children are selectivity and sensitivity. Drug Discovery Today: TARGETS, 2004, 3, 50-55.	0.5	1
105	Application of modular response analysis to medium- to large-size biological systems. PLoS Computational Biology, 2022, 18, e1009312.	1.5	1
106	Bioinformatics in MS-Based Proteomics. , 0, , 127-139.		0
107	311 Molecular networks in innate immunity. Cytokine, 2008, 43, 317.	1.4	0
108	Elucidating the molecular mechanism of action of cancer drugs in the second decade of the new millennium. Experimental Hematology, 2013, 41, S9.	0.2	0

#	Article	IF	CITATIONS
109	Systems Biology Analysis of Kinase Inhibitor Action in Leukemia Treatments. Biomedizinische Technik, 2013, 58 Suppl 1, .	0.9	0
110	Comparative functional analysis of the molecular network of 7 selected MLL fusion proteins. Experimental Hematology, 2014, 42, S60.	0.2	0
111	Comparative functional analysis of the molecular network of 7 selected MLL fusion proteins. Experimental Hematology, 2015, 43, S95.	0.2	0
112	Functional Genomic and Proteomic Characterization of Normal and Oncogenic CEBPA Variants In Myeloid Cells. Blood, 2010, 116, 3873-3873.	0.6	0
113	Analysis of Labeled Quantitative Mass Spectrometry Proteomics Data. , 2012, , 79-91.		0
114	Systems Biology Analysis of Kinase Inhibitor Protein Target Profiles in Leukemia Treatments. Lecture Notes in Computer Science, 2012, , 62-66.	1.0	0
115	Abstract IA2: Network models in oncogene-addicted lung cancer. Clinical Cancer Research, 2012, 18, IA2-IA2.	3.2	0
116	Abstract LB-099: A high-throughput screen of approved drugs uncovers a synergistic interaction targeting prostate cancer. , 2015, , .		0